University of Cantabria   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cantabria Spain (1972)

Organization Overview

First Clinical Trial
2000
NCT00560053
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Cantabria University | Fundación EPIC | Fundación Marques de Valdecilla | Fundación para el Progreso de la Oncología en Cantabria | Hospital Marques de Valdecilla | Hospital Marques de Valdecilla, Santander | Hospital Marques de Valdecilla. Santander. Spain | Hospital Universitario de Valdecilla | Hospital Universitario Marqués de Valdecilla | Hospital Valdecilla Santander | Instituto de Investigación Marqués de Valdecilla | Marques de Valdecilla Hospital | Marqués de Valdecilla University Hospital | University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Santander, Spain.

Active Ingredients

Drugs in Phase 4 Trials (11)

aripiprazole (abilify) (6 trials)

clopidogrel (plavix) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

ledipasvir (Harvoni) (1 trial)

mepolizumab (Nucala) (1 trial)

quetiapine (seroquel) (3 trials)

ringer's lactate (1 trial)

risperidone (risperdal) (3 trials)

sarilumab (kevzara) (1 trial)

sofosbuvir (sovaldi) (1 trial)

ziprasidone (geodon) (3 trials)

Drugs in Phase 3 Trials (17)

acetaminophen (tylenol) (1 trial)

allogeneic stem cells (1 trial)

autologous hematopoietic stem cells (1 trial)

autologous mononuclear stem cell (1 trial)

bortezomib (velcade) (1 trial)

colchicine (colbenemid) (1 trial)

dexamethasone (1 trial)

enoxaparin (lovenox) (1 trial)

fosfomycin (monurol) (1 trial)

Iberdomide (1 trial)

inactivated influenza vaccine (1 trial)

infliximab (remicade) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

Isatuximab (Sarclisa) (1 trial)

janssen SARS-CoV2 vaccine (1 trial)

lenalidomide (revlimid) (1 trial)

mrna-1273 (Spikevax) (1 trial)

Drugs in Phase 2 Trials (26)

ab154 (1 trial)

aflibercept (zaltrap) (1 trial)

axitinib (inlyta) (1 trial)

bevacizumab (avastin) (1 trial)

cabazitaxel (jevtana kit) (1 trial)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (1 trial)

catumaxomab (Removab) (1 trial)

cmv-specific t-cells (1 trial)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (2 trials)

doxorubicin (Doxil) (2 trials)

fluorouracil (efudex) (1 trial)

idp-121 (1 trial)

leucovorin (1 trial)

melatonin (1 trial)

octreotide (sandostatin) (1 trial)

oxaliplatin (eloxatin) (3 trials)

pembrolizumab (keytruda) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

sacituzumab govitecan (Trodelvy) (1 trial)

trastuzumab (herceptin) (1 trial)

trifolium pratense (1 trial)

vincristine (oncovin) (1 trial)

zimberelimab (1 trial)

Drugs in Phase 1 Trials (1)

human fecal microbiota (Reybota) (1 trial)

Drugs in Other Trials (1)

l-epigallocatechin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Atherosclerosis (Phase 4)

Carcinoma, Ovarian Epithelial (Phase 2)

Conjunctivitis (Phase 2)

Cytomegalovirus Infections (Phase 2)

Fatty Liver (Phase 1)

Fibrosis (Phase 3)

Giant Cell Arteritis (Phase 3)

Head and Neck Neoplasms (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Infections (Phase 4)

Influenza, Human (Phase 3)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Mental Disorders (Phase 4)

Mucositis (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Neuroendocrine Tumors (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 1)

Ovarian Neoplasms (Phase 2)

Pneumonia (Phase 3)

Polymyalgia Rheumatica (Phase 3)

Psychotic Disorders (Phase 4)

Rectal Neoplasms (Phase 2)

Schizophrenia (Phase 4)

Stomach Neoplasms (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial APIs: 56